Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?

  ()
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma. read more >

Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple

  ()
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." read more >

Biotech with Tenbagger Potential Signs Deal with Chinese Firm

Research Report
  ()
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans. read more >

Medical Device Firm to Launch Trials for Treatment Targeting $12 Billion Incontinence Market

Research Report
  ()
Anthony Vendetti, an analyst with Maxim Group, shared the results both of a pilot study for stress urinary incontinence and of a recent equity raise by this company. read more >

Company Takes Aim at Approval of Colorectal Cancer Screening Test in EU

  ()
Two analysts take note as this biotech prepares to release data on its colorectal cancer screening product. read more >

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle

Contributed Opinion
  ()
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. read more >

Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List

  ()
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. read more >
Expert Investing Ideas

"We are initiating coverage on RVX with a Buy rating."

–David Kideckel, Beacon Securities Ltd.


Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Research Report
  ()
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. read more >

Medical Device Firm Boosts Quarterly Revenue 50% YOY

Research Report
  ()
A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices. read more >

Coverage Initiated on Developer of Potential Breast Cancer Therapy Competitor

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe. read more >

Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis'

Research Report
  ()
H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer. read more >